Alan R Harvey Selected Research

Optic Nerve Injuries

1/2020	Intravitreal application of AAV-BDNF or mutant AAV-CRMP2 protects retinal ganglion cells and stabilizes axons and myelin after partial optic nerve injury.
1/2018	Retinal genes are differentially expressed in areas of primary versus secondary degeneration following partial optic nerve injury.
1/2017	Specific ion channels contribute to key elements of pathology during secondary degeneration following neurotrauma.
1/2014	Differential effects of 670 and 830 nm red near infrared irradiation therapy: a comparative study of optic nerve injury, retinal degeneration, traumatic brain and spinal cord injury.
1/2013	Adeno-associated virus-mediated expression of growth-associated protein-43 aggravates retinal ganglion cell death in experimental chronic glaucomatous injury.
12/2012	Changes in mRNA expression of class 3 semaphorins and their receptors in the adult rat retino-collicular system after unilateral optic nerve injury.
12/2011	Post-injury delivery of rAAV2-CNTF combined with short-term pharmacotherapy is neuroprotective and promotes extensive axonal regeneration after optic nerve trauma.
3/2010	Limited restoration of visual function after partial optic nerve injury; a time course study using the calcium channel blocker lomerizine.
12/2006	Cooperative effects of bcl-2 and AAV-mediated expression of CNTF on retinal ganglion cell survival and axonal regeneration in adult transgenic mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alan R Harvey Research Topics

Disease

9	Spinal Cord Injuries (Spinal Cord Injury) 06/2022 - 01/2013
9	Optic Nerve Injuries 01/2020 - 12/2006
5	Alzheimer Disease (Alzheimer's Disease) 01/2016 - 07/2007
4	Contusions 01/2021 - 09/2013
4	Wounds and Injuries (Trauma) 03/2015 - 01/2013
3	Ganglion Cysts (Ganglion) 01/2016 - 09/2004
2	Mental Disorders (Mental Disorder) 02/2022 - 08/2014
2	Inflammation (Inflammations) 01/2021 - 01/2016
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/2019 - 06/2012
2	Neoplasms (Cancer) 01/2018 - 01/2017
2	Hypertrophy 01/2017 - 02/2010
2	Cicatrix (Scar) 01/2017 - 01/2013
2	Gliosis 01/2016 - 07/2007
2	Glaucoma 01/2013 - 03/2010
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2012 - 07/2007
1	Stroke (Strokes) 06/2022
1	Traumatic Brain Injuries (Traumatic Brain Injury) 06/2022
1	type 2 Amaurosis congenita of Leber 12/2020
1	Nervous System Diseases (Neurological Disorders) 12/2019
1	Demyelinating Diseases (Demyelinating Disease) 10/2019
1	Cysts 01/2018
1	Genomic Instability 12/2017
1	Retinal Degeneration 01/2014
1	Multiple Sclerosis 06/2012
1	Disease Progression 06/2012
1	Necrosis 11/2009
1	Pathologic Processes 07/2007

Drug/Important Bio-Agent (IBA)

5	Proteins (Proteins, Gene)FDA Link 06/2022 - 06/2012
3	Nerve Growth Factors (Neurotrophins)IBA 09/2015 - 09/2004
2	Peptides (Polypeptides)IBA 06/2022 - 07/2007
2	CalciumIBA 01/2021 - 01/2017
2	Nogo Receptor 1IBA 10/2019 - 06/2012
2	Retinaldehyde (Retinal)IBA 01/2018 - 01/2016
2	TubulinIBA 01/2017 - 06/2012
2	Messenger RNA (mRNA)IBA 01/2016 - 12/2012
2	Coloring Agents (Dyes)IBA 01/2016 - 09/2004
2	Amyloid beta-PeptidesIBA 01/2013 - 07/2007
2	AndrogensIBA 06/2012 - 06/2009
2	lomerizineIBA 03/2010 - 11/2009
2	Caspase 3 (Caspase-3)IBA 11/2009 - 01/2005
1	Amyloid (Amyloid Fibrils)IBA 06/2022
1	Neuroprotective AgentsIBA 06/2022
1	PolymersIBA 01/2021
1	HydrogelsIBA 01/2021
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2020
1	biotinylated dextran amine (B-DA)IBA 01/2018
1	Ciliary Neurotrophic Factor (CNTF)IBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 12/2017
1	Long Noncoding RNAIBA 01/2017
1	Proteoglycans (Proteoglycan)IBA 01/2017
1	EnzymesIBA 01/2016
1	Evans Blue (Blue, Evans)FDA Link 01/2016
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 11/2014
1	8-hydroxyguanosineIBA 01/2014
1	fluorescent protein 583IBA 09/2013
1	GAP-43 Protein (GAP 43 Protein)IBA 01/2013
1	Toxic ActionsIBA 01/2013
1	Semaphorins (Semaphorin)IBA 12/2012
1	Nogo ReceptorsIBA 06/2012
1	Myelin-Oligodendrocyte GlycoproteinIBA 06/2012
1	Growth InhibitorsIBA 06/2012
1	Semaphorin-3AIBA 06/2012
1	Estrogens (Estrogen)FDA Link 06/2012
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 03/2010
1	Myelin Basic ProteinIBA 02/2010
1	AntioxidantsIBA 07/2007
1	diamidino yellowIBA 09/2004

Therapy/Procedure

7	Therapeutics 12/2020 - 12/2006
5	Transplantation 01/2016 - 07/2007
3	Transcranial Magnetic Stimulation 02/2022 - 08/2014
2	Lasers (Laser) 03/2015 - 01/2014
1	Cell Transplantation 01/2018
1	Injections 01/2018
1	Spinal Injections 01/2016
1	Intravenous Injections 01/2016
1	Phototherapy (Light Therapy) 03/2015
1	Semiconductor Lasers 01/2013
1	Drug Therapy (Chemotherapy) 12/2011